Medcaw Investments reports annual loss, cancels AML deal

Published 30/04/2025, 15:28
Medcaw Investments reports annual loss, cancels AML deal

LONDON - Medcaw Investments Plc, a company focused on pursuing acquisitions, disclosed its audited financial results for the year ended December 31, 2024, revealing a net loss and the cancellation of a proposed transaction with Abyssinian Metals Limited (AML).

The results, announced on April 30, 2025, showed a loss for the year of £432,360, compared to a loss of £712,170 in the previous year. The company reported no revenue for either year. Administrative expenses were reduced to £267,097 from £562,260, and the company recognized an impairment of £196,141. The basic and diluted loss per share decreased to 1.95 pence from 3.64 pence.

Medcaw’s net liabilities stood at £163,304 as of December 31, 2024, a decrease from net assets of £269,056 the previous year. The company’s cash and cash equivalents significantly dropped to £72,286 from £371,484.

The company also provided an update on the proposed reverse transaction with AML, initially announced on July 7, 2023. The board decided not to proceed with the transaction due to an ongoing dispute between AML and the Federal Democratic Republic of Ethiopia concerning the Kenticha Lithium project. Medcaw’s shares, which had been suspended, resumed trading on the London Stock Exchange (LON:LSEG) on April 2, 2025.

Following the cancellation of the AML deal, the directors have initiated the search for a new acquisition target. The Chairman, Marcus Yeoman, expressed gratitude to shareholders, directors, and colleagues at Orana Corporate LLP for their support during this period.

The financial statements have been prepared on a going concern basis, despite recurring losses and the company’s dependence on obtaining additional financing. The auditors have included a material uncertainty note regarding the company’s ability to continue as a going concern.

This news article is based on a press release statement by Medcaw Investments Plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.